Abstract 295P
Background
Volumetric arc therapy (VMAT) with Simultaneous Integrated Boost (SIB) allows radiotherapy dose escalation to the region of involved nodes also reducing toxicity in node-positive patients of cervical cancer. Aim of this study was to evaluate the early outcome and acute toxicity with chemo-radiation usingVMAT with SIB in patients with locally advanced cervical cancer.
Methods
Thirty-three newly diagnosed cases of carcinoma cervix having Positron emission tomography (PET) positive pelvic/para-aortic nodes were included after obtaining a written informed consent. The complete clinical assessment and staging was performed. All patients were treated by VMAT with SIB technique to the dose of 50.4Gy to the primary site with draining nodes and 58.8Gy to PET positive nodes in 28 fractions followed by HDR brachytherapy boost of 7Gy in three fractions. Concurrent cisplatin at the dose of 40mg/m2 was administered on weekly basis during External beam radiotherapy. Acute toxicity was assessed according to the RTOG Acute Radiation Morbidity scoring criteria. Post treatment response was assessed by clinical examination and PET-CT /CECT scans at 3months.
Results
Median age was 55 years(range 35-70). The mean tumor size was 5.7cm (range 3.5-9) with 90% patients having disease more than 4cm. Median Standardized uptake value maximum in PET at primary tumor and LN was 17.3 and 8.7 respectively. Pelvic node only was seen in 23(69.6%) patients while Para-aortic node was involved in ten. Bladder and rectum invasion was seen in four and two patients respectively.Twenty-six (79%) patients received four or more cycles of concurrent Cisplatin. The median overall treatment time was 62 days. Response assessment at 3months showed complete response in 27 patients (82%), partial response in four while progressive disease in two patients. Maximum grade of toxicity at 3 months in skin, gastrointestinal, and hematological was grade I whereas one patient had grade III genitourinary toxicity. At last follow up, 30 patients were alive while three patients died; two deaths due to disease.
Conclusions
VMAT with SIB to involved nodes to higher doses results in effective early loco-regional control with acceptable acute toxicities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Mishra.
Funding
Institute of Eminence, Banaras Hindu University, Varanasi.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract